Article
Medicine, Research & Experimental
Akshay Sharma, Gatha Thacker, Mukul Mishra, Anil Kumar Singh, Vishal Upadhyay, Sabyasachi Sanyal, Arun Kumar Trivedi
Summary: In this study, we found that SOX4 positively regulates FBW7 expression at the transcriptional level by binding to the FBW7 promoter. We also observed a positive correlation between SOX4 and FBW7 mRNA levels in ER+ breast cancer cell lines and patient samples. Our findings suggest that increased levels of SOX4 and FBW7 promote cancer stemness and tumor cell dormancy. Additionally, the upregulation of SOX4 enhances FBW7-mediated degradation of GATA3, leading to tamoxifen resistance.
Article
Cell Biology
Ramesh Elango, Sameera Rashid, Radhakrishnan Vishnubalaji, Reem Al-Sarraf, Mohammed Akhtar, Khalid Ouararhni, Julie Decock, Omar M. E. Albagha, Nehad M. M. Alajez
Summary: By performing transcriptomic profiling on breast cancer patients from Qatar, we identified differential gene and miRNA expression patterns based on molecular subtypes, tumor grade, patients' age, and ethnicity. We uncovered miRNA-mRNA regulatory networks and potential therapeutic targets, and validated mRNA and miRNA-based signatures predictive of relapse free survival.
CELL DEATH & DISEASE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Eunhye Lee, Boyoung Park
Summary: Breast density changes over time are associated with breast cancer risk in both premenopausal and postmenopausal women. Continuous increase in breast density increases the future risk of breast cancer, while continuous decrease in breast density is associated with a lower risk.
Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Medicine, Research & Experimental
Feng Bai, Li-Han Zhang, Xiong Liu, Chuying Wang, Chenglong Zheng, Jianping Sun, Min Li, Wei-Guo Zhu, Xin-Hai Pei
Summary: The study reveals a positive correlation between BRCA1 and GATA3 expression in human breast cancers. Depletion of BRCA1 stimulates methylation of GATA3 promoter, repressing GATA3 transcription. Additionally, GATA3 deficiency induces poorly-differentiated mammary tumors with activated EMT and increased metastatic potential.
Article
Oncology
Milena Foerster, Valerie McCormack, Benjamin O. Anderson, Pauline Boucheron, Annelle Zietsman, Herbert Cubasch, Maureen Joffe, Angelica Anele, Shadrach Offiah, Moses Galukande, Groesbeck Parham, Leeya F. Pinder, Ophira Ginsburg, Joachim Schuez, Isabel dos-Santos-Silva, Eva J. Kantelhardt
Summary: This study examined the treatment initiation, guideline concordance, and abandonment in patients with non-metastatic breast cancer in sub-Saharan Africa, highlighting the need for improved treatment access and completion to prevent premature breast cancer deaths.
Editorial Material
Medicine, General & Internal
Alice Y. Ho, Jennifer R. Bellon
Summary: In this Journal article, the 10-year results of the anticipated PRIME II trial are reported. The results suggest that omitting radiotherapy after breast-conserving surgery has no impact on survival in women aged 65 or older with low-risk breast cancer. These findings address the issue of overtreatment in older women with low-risk breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Thi Xuan Mai Tran, Yoosoo Chang, Soyeoun Kim, Huiyeon Song, Seungho Ryu, Boyoung Park
Summary: This study investigated the association between family history of breast cancer (FHBC) and mammographic breast density and density changes among premenopausal women. The results showed that women with FHBC had higher breast density, and the association varied depending on the affected relatives. These findings emphasize the importance of tailored breast cancer risk assessment for women with FHBC.
Article
Biochemistry & Molecular Biology
Gianluca Aguiari, Francesca Crudele, Cristian Taccioli, Linda Minotti, Fabio Corra, Jeffrey W. Keillor, Silvia Grassilli, Carlo Cervellati, Stefano Volinia, Carlo M. Bergamini, Nicoletta Bianchi
Summary: The role of transglutaminase type 2 in cell physiology involves protein transamidation and signal transduction, which affect various cellular processes. In breast cancer, TG2 plays a significant role in disease progression, particularly in promoting cell motility, epithelial-mesenchymal transition, invasion, and drug resistance. This study aims to clarify the interconnections between TGM2 variants and transcription factors associated with aggressive phenotypes in breast cancer.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Minami Hatono, Hirokuni Ikeda, Yoko Suzuki, Yukiko Kajiwara, Kengo Kawada, Takahiro Tsukioki, Mariko Kochi, Ken Suzawa, Takayuki Iwamoto, Hiromasa Yamamoto, Tadahiko Shien, Masaomi Yamane, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka
Summary: Isoflavones metabolite equol has dual effects on breast cancer, promoting tumor growth at low concentrations in hormone receptor-positive cells and exhibiting antitumor effects at high doses. When used with tamoxifen, equol may have antagonistic effects depending on concentration, but does not show antagonistic effects with other therapeutic agents.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Christopher Li, Meghan R. Flanagan, Mei-Tzu C. Tang, Peggy L. Porter, Kathleen E. Malone
Summary: This study demonstrates that bisphosphonate use is associated with a lower risk of subsequent invasive breast cancer among women with a history of DCIS, suggesting a potential preventative approach for this high-risk population.
Review
Biochemistry & Molecular Biology
Sunil Kumar Dubey, Tanya Bhatt, Mukta Agrawal, Ranendra Narayan Saha, Swarnlata Saraf, Shailendra Saraf, Amit Alexander
Summary: Breast cancer, one of the most invasive cancers in women with high mortality rates, can potentially be targeted and treated more effectively using chitosan-based nanocarriers, which offer unique advantages in overcoming the limitations of current therapies. Research in this area has been focused on exploring novel techniques and improving targeted therapy for breast cancer, with promising results in recent years.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Medicine, Research & Experimental
Sewon Hwang, Soojun Park, Jee Hyun Kim, Sang-Beom Bang, Hyeon-Ji Kim, Na-Lee Ka, Yoonae Ko, Seung-Su Kim, Ga Young Lim, Seunghee Lee, Young Kee Shin, So Yeon Park, Sanghee Kim, Mi-Ock Lee
Summary: This study aimed to identify lipid metabolic perturbations in tamoxifen-resistant breast cancer (BC) and investigate the role of HMGCS2 in BC growth. Comprehensive metabolomics and transcriptomics analysis were conducted. The upregulation of HMGCS2 was verified in tamoxifen-resistant BC cells and clinical samples. A HMGCS2 inhibitor was discovered and its effect on tumor growth was studied.
Review
Pharmacology & Pharmacy
Zhen Zhu, Hongyu Shen, Jialin Xu, Zheng Fang, Guanqun Wo, Ying Ma, Kai Yang, Yalin Wang, Qiang Yu, Jin-hai Tang
Summary: Doxorubicin-induced basal breast cancer cell death depends on iron-mediated ferroptosis. Over-expression of the luminal signature transcriptional factor GATA3 promotes doxorubicin resistance by inhibiting CYB5R2-mediated iron metabolism and ferroptosis. Breast cancer patients with high GATA3 expression may not benefit from doxorubicin-based neoadjuvant chemotherapy regimens.
DRUG RESISTANCE UPDATES
(2023)